← Back to Treatments
🏅 FDA Orphan Designation

Epidiolex

CANNABIDIOL

Manufacturer: Jazz Pharmaceuticals, Inc.

Indicated for:
Lennox-Gastaut syndromeOrphanDravet syndromeTuberous sclerosis complex

FDA-Approved Indications (3)

Lennox-Gastaut syndromeOrphan Designation

EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.

EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 1 year of age and older

Population: pediatric ≥1 year

EPIDIOLEX is indicated for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older

Population: pediatric ≥1 year

Indications & Usage

1 INDICATIONS AND USAGE EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )

💙 Support Programs

View all →
Epidiolex
Jazz Pharmaceuticals, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.